Boswellia (Frankincense) for Anti-Inflammatory

Research suggests that Boswellia (frankincense) has meaningful anti-inflammatory properties, primarily attributed to boswellic acids — especially acetyl-11-keto-β-boswellic acid (AKBA) — which appear to work by inhibiting key inflammatory pathways including 5-lipoxygenase, leukotriene synthesis, cyclooxygenase enzymes, and prostaglandin E2 production through multiple molecular targets. The available evidence base consists largely of in vitro studies, animal models, and narrative or systematic reviews, with some clinical trials supporting effectiveness in conditions such as osteoarthritis, asthma, inflammatory bowel conditions, and psoriasis, though researchers consistently note that more rigorous and large-scale human trials are needed before definitive conclusions can be drawn. Studies indicate that additional bioactive compounds beyond boswellic acids — including cembranoids, diterpenoids like incensole acetate, and triterpene acids such as tirucallic and lupeolic acids — also contribute to the anti-inflammatory effects, suggesting the resin's activity is more complex than early research recognized. A notable limitation flagged across multiple reviews is the poor oral bioavailability of boswellic acids, which raises questions about how well laboratory and animal findings translate to real-world human use, and researchers have identified improved formulation strategies and chemical modification as areas requiring further development.